profit from every ₹100 of sales.
₹0₹100
Senores Pharmaceuticals
₹1,174.00-3.44% today
+44.0% in 1 year
1-year low ₹711.501-year high ₹1,552.80
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2026.
0%20% a year
You pay ₹46.86 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Senores Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from ₹353 million in 2023 to ₹6.33 billion in 2026, with ₹1.15 billion of profit last year.
SalesProfit
Senores Pharmaceuticals vs. similar companies
Senores Pharmaceuticals grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Senores Pharmaceuticals | 46.9× · Expensive | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Senores Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| 353 | 2,108 | 3,983 | 6,326 | |
| 226 | 996 | 2,176 | 3,810 | |
| 109 | 317 | 729 | 1,371 | |
| 161 | 435 | 1,090 | 2,154 | |
| 84 | 315 | 586 | 1,154 | |
| 1.83 | 6.83 | 16.12 | 26.39 | |
| 63.9% | 47.3% | 54.6% | 60.2% | |
| 30.8% | 15.1% | 18.3% | 21.7% | |
| 23.9% | 14.9% | 14.7% | 18.2% |
Balance sheet
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total assets | 1,311 | 6,219 | 12,269 | 16,038 |
| Cash | 1 | 77 | 1,054 | 456 |
| Total debt | 626 | 2,576 | 3,148 | 3,420 |
| Total liabilities | 856 | 3,902 | 4,146 | 6,393 |
| 455 | 2,043 | 7,862 | 9,336 | |
| 46 | 46 | 36 | 44 | |
| 10.4% | 5.7% | 6.6% | 11.4% | |
| 18.5% | 15.4% | 7.4% | 12.4% |
Cash flow
| In millions of INR | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| -11 | -257 | -459 | 621 | |
| 473 | 518 | 1,575 | 2,647 | |
| -484 | -775 | -2,034 | -2,027 | |
| Dividends paid | – | – | – | – |
| – | – | – | 19 | |
| – | – | – | – |
Valuation
- 46.9×
- –
- 0.33
- 5.7×
- 8.5×
- –
- 26.5×
- -3.7%
- 2.1%
- –
Profitability
- 60.2%
- 21.7%
- 18.2%
- –
- 10.8%
- 8.1%
- –
- –
- –
- –
Growth
- +161.6%
- +143.4%
- –
- –
- −1.7%
Financial health
- 1.4×
- 0.37
- –
- 7.4×
- 1.92
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 26%of 963
Top 22%of 894
Bottom 26%of 632
Top 3%of 908
Bottom 19%of 991
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
38No pass
Philip Fisher
65Pass
Peter Lynch
98Pass
Joel Greenblatt
8No pass
Charlie Munger
44No pass
Terry Smith
35No pass
Questions about Senores Pharmaceuticals
Is Senores Pharmaceuticals a good stock to buy?
A solid business, but the price is high. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Senores Pharmaceuticals AI analysis
What does Senores Pharmaceuticals do?
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It is in Drug Manufacturers - General, based in Ahmedabad, India.
Is Senores Pharmaceuticals stock halal?
Yes. Senores Pharmaceuticals passes our halal screen: its business is permitted and its debt is 6% of its market value, under the 30% limit. How we check
How has Senores Pharmaceuticals stock done over the past year?
Up 44.0% over the past twelve months, to ₹1,174.00. It traded between ₹711.50 and ₹1,552.80 and is 24.4% below its high.
Who are Senores Pharmaceuticals's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Senores Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.